220 related articles for article (PubMed ID: 20525753)
1. Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.
Kornblau SM; Minden MD; Rosen DB; Putta S; Cohen A; Covey T; Spellmeyer DC; Fantl WJ; Gayko U; Cesano A
Clin Cancer Res; 2010 Jul; 16(14):3721-33. PubMed ID: 20525753
[TBL] [Abstract][Full Text] [Related]
2. Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.
Cesano A; Putta S; Rosen DB; Cohen AC; Gayko U; Mathi K; Woronicz J; Hawtin RE; Cripe L; Sun Z; Tallman MS; Paietta E
PLoS One; 2013; 8(2):e56714. PubMed ID: 23431389
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).
Rosen DB; Minden MD; Kornblau SM; Cohen A; Gayko U; Putta S; Woronicz J; Evensen E; Fantl WJ; Cesano A
PLoS One; 2010 Oct; 5(10):e13543. PubMed ID: 21048955
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
Lacayo NJ; Alonzo TA; Gayko U; Rosen DB; Westfall M; Purvis N; Putta S; Louie B; Hackett J; Cohen AC; Cesano A; Gerbing R; Ravindranath Y; Dahl GV; Gamis A; Meshinchi S
Br J Haematol; 2013 Jul; 162(2):250-62. PubMed ID: 23682827
[TBL] [Abstract][Full Text] [Related]
5. Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia.
Cesano A; Willman CL; Kopecky KJ; Gayko U; Putta S; Louie B; Westfall M; Purvis N; Spellmeyer DC; Marimpietri C; Cohen AC; Hackett J; Shi J; Walker MG; Sun Z; Paietta E; Tallman MS; Cripe LD; Atwater S; Appelbaum FR; Radich JP
PLoS One; 2015; 10(4):e0118485. PubMed ID: 25884949
[TBL] [Abstract][Full Text] [Related]
6. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.
Pierceall WE; Kornblau SM; Carlson NE; Huang X; Blake N; Lena R; Elashoff M; Konopleva M; Cardone MH; Andreeff M
Mol Cancer Ther; 2013 Dec; 12(12):2940-9. PubMed ID: 24092807
[TBL] [Abstract][Full Text] [Related]
7. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
8. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
11. Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts.
Cesano A; Rosen DB; O'Meara P; Putta S; Gayko U; Spellmeyer DC; Cripe LD; Sun Z; Uno H; Litzow MR; Tallman MS; Paietta E
Cytometry B Clin Cytom; 2012 May; 82(3):158-72. PubMed ID: 22334473
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
[TBL] [Abstract][Full Text] [Related]
13. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
Mehta SV; Shukla SN; Vora HH
Neoplasma; 2013; 60(6):666-75. PubMed ID: 23906301
[TBL] [Abstract][Full Text] [Related]
15. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
[TBL] [Abstract][Full Text] [Related]
16. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
Ravandi F; Kantarjian H; Faderl S; Garcia-Manero G; O'Brien S; Koller C; Pierce S; Brandt M; Kennedy D; Cortes J; Beran M
Leuk Res; 2010 Jun; 34(6):752-6. PubMed ID: 19878996
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia.
Rosen DB; Putta S; Covey T; Huang YW; Nolan GP; Cesano A; Minden MD; Fantl WJ
PLoS One; 2010 Aug; 5(8):e12405. PubMed ID: 20811632
[TBL] [Abstract][Full Text] [Related]
20. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
